Year: 2023

ImmuPharma PLC (LSE AIM: IMM – Euronext Growth: ALIMM), the specialist drug discovery and development company, confirms that the Annual Report and Accounts for the year ended 31 December 2019, and the Notice of Annual General Meeting has been posted to shareholders. These documents are available, in electronic form, for download on the Company’s website…

Click here for information IMM RNS Form TR1 Lanstead 18 May 2020

ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company provides a progress update on activities around Covid-19.  On 30 March 2020, ImmuPharma announced that it had expanded its pipeline to include three new ‘Anti-Infective’ programs, one of which was in ‘Antivirals’. Investigation of the application of the Ureka peptide technologies…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company confirms that the Audited Annual Report and Accounts (“Report”) for the year ended 31 December 2019, has today been published on the Company’s website. Copies of this Report, including the Notice of Annual General Meeting, will be posted to shareholders in…

ImmuPharma plc (LSE:IMM), (Euronext Growth Brussels: ALIMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its final results for the twelve months ended 31 December 2019 (the “Period”).  Key Highlights (including post Period review) Stable financial performance over the Period – Cash balance of £1.4 million (31 December 2018:  £4.9…

ImmuPharma PLC (LSE AIM: IMM – Euronext Growth: ALIMM), a specialist drug discovery and development company, is pleased to announce that Tim McCarthy, Chairman of ImmuPharma, will provide a live presentation relating to the recently announced (30/3/20) £1.5 million Subscription and update on the Company’s R&D programmes, via the ‘Investor Meet Company’ platform. The live…

TR1 – Notification of major interest in shares by Lanstead Capital – 3 April 2020 To view document click here

TR1 – Notification of major interest in shares from Robert Zimmer – 2 April 2020 To view document click here

ImmuPharma PLC (LSE AIM: IMM – Euronext Growth: ALIMM), the specialist drug discovery and development company, is pleased to announce subscriptions to raise £1.5 million (the “Subscriptions”) through the issue of 15,000,000 new ordinary share of 10 pence each in the Company (“Ordinary Shares”) (the “Subscription Shares”) at a price of 10p per Ordinary Share…

ImmuPharma PLC (LSE AIM: IMM – Euronext Growth: ALIMM), a specialist drug discovery and development company, notes that further to its announcement on 17 February 2020, Incanthera plc (“Incanthera”), a specialist oncology company, has today been admitted to the NEX Exchange Growth Market (TIDM: INC) and has published its Admission Document. Following Admission to trading,…